CARPEDIEM: Coronary Artery Plaque Burden and Morphology in Type 2 Diabetes Mellitus.

Sponsor
Svendborg Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03016910
Collaborator
(none)
350
1
42
8.3

Study Details

Study Description

Brief Summary

Unstable plaque, the primary cause of myocardial infarction, is characterized by distinct a morphology including positive remodeling (PR), low attenuated plaque (LAP), napkin ring sign (NRS), and spotty calcifications (SC) The purpose of the present study is to investigate the influence of microvascular dysfunction and additional risk factors on plaque morphology and plaque burden in patients with diabetes mellitus.

Detailed Description

Coronary artery disease (CAD) is the leading cause of death and morbidity in type 2 diabetes mellitus (T2DM) and diabetics holds the same risk for death or myocardial infarction (MI) as patients with a prior (MI) without diabetes. In addition to macrovascular complications, and traditional cardiac risk factors, T2DM is burdened by microvascular dysfunction affecting several organs. The dynamics between microvascular dysfunction, known cardiac risk factors and coronary atherosclerosis in diabetic disease is not well characterized.

In the present study, a primary cohort of 300 type 2 diabetics and a subgroup of 50-100 type 1 diabetics will be examined with CCTA at baseline and after one year. In addition, CAD in diabetes will be compared to a historical cohort of patients with acute myocardial infarction (AMI).

All study participant will undergo the following examinations at baseline:
  • CCTA

  • CAC-score

  • Transthoracic echocardiography

  • 12-lead ECG

  • Blood pressure and pulse frequency

  • Height, weight, waist to hip-ratio

  • Blood samples and urin samples

  • Medical history

After 12 months all of the above examinations will be repeated.

Study Design

Study Type:
Observational
Anticipated Enrollment :
350 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Coronary Artery Plaque Burden in Type 2 Diabetes Mellitus. Changes Over Time, Relation to Risk Profile, and Comparison to Acute Myocardial Infarction.
Study Start Date :
Mar 1, 2016
Anticipated Primary Completion Date :
Mar 1, 2019
Anticipated Study Completion Date :
Sep 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Type 2 diabetes

This group will consist of 300 patients with type 2 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year and CCTA will be performed at baseline and after one year.

Type 1 diabetes

This group will consist of 50-100 patients with type 1 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year. CCTA will be performed at baseline and after one year.

Outcome Measures

Primary Outcome Measures

  1. Changes in plaque burden stratified by diabetic complications. [Baseline,12 months.]

    Changes in plaque burden (percentage) during 12 months in diabetics with or without diabetic complications.

  2. Changes in plaque burden stratified by cardiovascular risk factors [Baseline, 12 months]

    Changes in plaque burden during 12 months stratified by cardiovascular risk factors (hypertension,hypercholersterolemia, smoking, overweight/obesity)

  3. Changes in plaque morphology stratified by diabetic complications [Baseline, 12 months]

    Changes in plaque morphology (PR, LAP, NRS, SC) during 12 months in diabetics either with or without diabetic complications.

  4. Changes in plaque morphology stratified by cardiovascular risk factors. [Baseline,12 months]

    Changes in plaque burden during 12-months stratified by cardiovascular risk factors

Secondary Outcome Measures

  1. Changes in plaque burden in diabetes compared to AMI-patients without diabetes. [Baseline and 12 months]

    A comparison of plaque burden (percentage) in diabetes and a historical cohort of AMI-patients.

  2. Changes in plaque morphology in diabetes compared to AMI-patients without diabetes. [Baseline,12-months]

    A comparison of plaque morphology in diabetes and a historical cohort of AMI-patients.

  3. Changes in plaque burden during 12 months in relation to HbA1c and cholesterol levels. [Baseline,12-months]

    Changes in plaque burden during 12 months stratified by historical levels of cholesterol and HbA1c levels recorded from onset of diabetes to present.

  4. Changes in plaque morphology during 12 months in relation to HbA1c and cholesterol levels. [Baseline,12-months]

    Changes in plaque morphology during 12 months stratified by historical levels of cholesterol and HbA1c levels recorded once a year from onset of diabetes to present.

  5. Impact of asymtomatic CAD in diabetes on future events. [5-7 years]

    Long term follow-up to evaluate the impact of asymptomatic CAD (plaque burden and morphology) in diabetes on death, coronary heart attack, hospitalization due to unstable angina, heart failure and ischemic stroke. Clinical outcomes will be recorded from journal records and analyzed after 5-7 years.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age > 18 years

  • Type 1 or 2 diabetes mellitus

  • Ability to provide informed conscent

Exclusion Criteria:
  • History of CAD

  • Symtoms of CAD (angina)

  • Any tachyarrhythmias making CCTA impossible

  • Glumerular filtration rate (GFR)< 45 ml/min

  • Allergy to iodine contrast

  • Critical illness with life expectancy less than 1 year

  • Documented heart failure

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Odense (OUH) Svendborg Hospital Svendborg Fyn Denmark 5700

Sponsors and Collaborators

  • Svendborg Hospital

Investigators

  • Study Director: Kenneth Egstrup, Prof. DMSci, Head of Reseach, Cardiovascular Research Unit, OUH Svendborg Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Laurits Heinsen, Medical doctor, Svendborg Hospital
ClinicalTrials.gov Identifier:
NCT03016910
Other Study ID Numbers:
  • CD20150029
First Posted:
Jan 11, 2017
Last Update Posted:
Jan 11, 2017
Last Verified:
Jan 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2017